Emerging analgesic drugs for Parkinson's disease

Pérez-Lloret, Santiago; Rey, María Verónica; Dellapina, Estelle; Pellaprat, Jean; Brefel‐Courbon, Christine; Rascol, Olivier

doi:10.1517/14728214.2012.677949

Cited by 37 publications

(31 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However a study by Fox et al () has shown that naloxone did not reduce the levodopa‐induced dyskinesia. Opioid could also be used to treat pain symptoms in patients with PD (Madeo et al, ; Perez‐Lloret et al, ).…”

Section: Related Therapeutic Interventionmentioning

confidence: 99%

Updates on immunity and inflammation in Parkinson disease pathology

Joshi

Singh

2017

J of Neuroscience Research

View full text Add to dashboard Cite

Studies in the last decade have suggested the association of both neuroinflammatory processes and immune responses in Parkinson disease (PD) pathology. PD pathology is related to depleted dopamine levels, α-synuclein aggregation, and death of nigrostriatal dopaminergic neurons. Reports have suggested central and peripheral inflammation in the prodromal stage of the disease, which is sustained during disease progression. Alongside the activation of peripheral immune system exacerbates the dissonant central inflammatory responses and could contribute in synergistic neurodegeneration. Activated glial cells contribute significantly in the neuroinflammatory process during the occurrence of the disease and are also acknowledged as a hallmark of disease progression. However, the contribution of glial cells is not well defined in the context of neurodegeneration and neuroprotection. This review provides an overview of the roles of immune and inflammatory responses and their consequences in PD disease pathogenesis and also discusses possible therapeutic strategies for PD based on these findings.

show abstract

Section: Related Therapeutic Interventionmentioning

confidence: 99%

Updates on immunity and inflammation in Parkinson disease pathology

Joshi

Singh

2017

J of Neuroscience Research

View full text Add to dashboard Cite

show abstract

“…Once pain in PD patients has been correctly classified according to subtype and separated from pain associated with comorbid conditions (most commonly osteoarthritis but also other conditions such as diabetes and rheumatological conditions), the management of pain with various pharmacological and nonpharmacological therapies may be initiated. Patients who have pain associated with rigidity due to parkinsonism may have damage to nonneural tissue due to muscle/joint stretching and subsequent inflammation [36]. These patients may benefit from nonpharmacological treatment such as stretching exercises, repetitive transcranial magnetic stimulation or cranial electrotherapy stimulation.…”

Section: Discussionmentioning

confidence: 99%

Clinical Study on Chronic Pain in Parkinson's Disease Patients in Shanghai, China

Pan

Wang

et al. 2014

Integr Med Int

View full text Add to dashboard Cite

Background/Aims: Pain in Parkinson's disease (PD) may be more distressing than that in other nonmotor disabilities. The aims of the present study were to assess the prevalence and identify the epidemiological characteristics of PD-related pain among patients with idiopathic PD in Shanghai, China. Methods: A total of 1,058 patients with definite idiopathic PD were investigated using a structure questionnaire in 12 hospitals in Shanghai. The severity of their motor disorders, antiparkinson treatments, and pain-related observations, such as time points for the onset of pain, duration and degree, body localization, external influences, and treatments for pain, were collected for analysis. Results: Approximately 28% (296 subjects) of all PD patients suffered from PD-related pain. Female patients with pain had a higher age level, were older at PD onset, had a higher frequency of pain, a higher frequency of pain before the onset of PD symptoms, a longer duration of pain, and a higher incidence of pain in the early stage compared to male patients. Larger levodopa-equivalent doses, higher frequencies of sleep disorders and/or motor fluctuation, and/or dyskinesia were found in patients with pain compared to patients without pain. The most frequent pain type was musculoskeletal pain followed by dystonia. The male group had a much shorter pain duration than the female group. The patients experienced more pain before taking antiparkinson drugs compared to after treatment. Conclusion: Chronic PD-related pain is a frequent complaint and complex in PD. The challenge of managing pain in PD patients will hopefully someday result in specific and effective treatment strategies. i 2014 S. Karger AG, Basel

show abstract

“…Such compounds may be effective analgesics both for PD and for other painful disorders linked to disrupted endogenous dopamine activity such as fibromyalgia, burning mouth syndrome and painful diabetic neuropathy [31,63]. Furthermore, if the suggestion that the underuse of conventional painkillers in PD patients is attributable to poor efficacy in this group [44], such medications could provide potentially superior alternatives. The utility of such analgesics could even extend to conventional treatment in healthy individuals with pain.…”

Section: Role Of Dopaminementioning

confidence: 99%